Davern Capital Partners, LP
In its 13F for Q1 2026 (holdings as of March 31, 2026, filed May 14, 2026), Davern Capital Partners, LP reported 17 stock positions worth $364.5 million. Its top holding was Pfizer (PFE) at 12.3% of the portfolio, followed by Regeneron Pharmaceuticals (REGN, 9.5%) and Insmed (INSM, 8.2%). Compared with Q4 2025, it opened 4 new positions, sold out of 1, added to 7 and reduced 6. The biggest buy was a new position in Insmed (INSM) and the biggest sale Pfizer (PFE, shares −22%).
- Most Recent 13F
- Q2 2026
- Location
- NY, NY
- CIK
- 0002003147
- Portfolio Value
- $364.5M (Q1 2026)
- SEC Filing
- 0000905148-26-002267 ↗ filed May 14, 2026
Holdings Value
Holdings 17 stocks · $364.5M
| PFE Pfizer Inc. | 12.28% | 1,593,942 | $44.8M | Reduce -21.9% |
| REGN Regeneron Pharmaceuticals | 9.50% | 44,800 | $34.6M | Reduce -14.5% |
| INSM Insmed Inc. | 8.19% | 182,562 | $29.9M | New |
| IONS Ionis Pharmaceuticals Inc. | 7.97% | 386,903 | $29.1M | Add +62.2% |
| NTRA Natera Inc. | 7.90% | 143,966 | $28.8M | Add +83.0% |
| BNTX Biontech SE-ADR | 7.44% | 305,055 | $27.1M | Reduce -17.8% |
| ARGX Argenx SE - ADR | 7.02% | 35,045 | $25.6M | Reduce -1.8% |
| LLY Eli Lilly & Co. | 6.88% | 27,279 | $25.1M | Add +228.4% |
| RPRX Royalty Pharma PLC Class A | 6.84% | 520,009 | $24.9M | Reduce -38.1% |
| ROIV Roivant Sciences Ltd. | 6.64% | 873,398 | $24.2M | Reduce -15.1% |
| LEGN Legend Biotech Corp.-ADR | 6.52% | 1,314,748 | $23.8M | Add +24.4% |
| MLYS Mineralys Therapeutics Inc. | 3.32% | 447,153 | $12.1M | Add +112.3% |
| ABVX Abivax SA-ADR | 2.39% | 78,125 | $8.7M | Add +61.1% |
| GENB Generate Biomedicines Inc. | 2.03% | 591,800 | $7.4M | New |
| PRCT Procept Biorobotics Corp. | 1.79% | 261,200 | $6.5M | New |
| GPCR Structure Therapeutics Inc. | 1.67% | 126,461 | $6.1M | New |
| VRDN Viridian Therapeutics Inc. | 1.62% | 302,457 | $5.9M | Add +15.6% |
Portfolio Sells Q4 2025 → Q1 2026
| PFE Pfizer Inc. | Reduce -21.9% | 12.28% | −4.16 |
| BNTX Biontech SE-ADR | Reduce -17.8% | 7.44% | −3.99 |
| RPRX Royalty Pharma PLC Class A | Reduce -38.1% | 6.84% | −3.66 |
| REGN Regeneron Pharmaceuticals | Reduce -14.5% | 9.50% | −3.59 |
| ARGX Argenx SE - ADR | Reduce -1.8% | 7.02% | −2.68 |
| CGON CG Oncology Inc. | Sold out | 0.00% | −2.17 |
| ROIV Roivant Sciences Ltd. | Reduce -15.1% | 6.64% | −0.58 |
Portfolio Buys Q4 2025 → Q1 2026
| INSM Insmed Inc. | New | 8.19% | +8.19 |
| LLY Eli Lilly & Co. | Add +228.4% | 6.88% | +4.00 |
| NTRA Natera Inc. | Add +83.0% | 7.90% | +2.07 |
| GENB Generate Biomedicines Inc. | New | 2.03% | +2.03 |
| IONS Ionis Pharmaceuticals Inc. | Add +62.2% | 7.97% | +1.87 |
| PRCT Procept Biorobotics Corp. | New | 1.79% | +1.79 |
| GPCR Structure Therapeutics Inc. | New | 1.67% | +1.67 |
| MLYS Mineralys Therapeutics Inc. | Add +112.3% | 3.32% | +0.85 |
| ABVX Abivax SA-ADR | Add +61.1% | 2.39% | +0.27 |
| LEGN Legend Biotech Corp.-ADR | Add +24.4% | 6.52% | −0.90 |
| VRDN Viridian Therapeutics Inc. | Add +15.6% | 1.62% | −1.01 |